<DOC>
	<DOCNO>NCT00521963</DOCNO>
	<brief_summary>Intra-articular ( IA ) injection medication common procedure management joint disorder . In particular , procedure effective treatment inflammatory condition , long act corticosteroid commonly use . These agent show reduce sign symptoms inflammation , express primarily synovium joint , probably capable slow progression damage joint cartilage bone inflammatory condition . Arthritis refractory IA corticosteroid injection may respond surgical , chemical , , radioisotope synovectomy , procedure inflame synovial tissue eradicate . It note infliximab , monoclonal antibody direct Tumor Necrosis Factor ( TNF ) - α , high affinity TNF-α rich inflame synovium . Recently , clinical benefit IA injection infliximab report case refractory IA injection corticosteroid . Similarly , effectiveness IA infliximab suppression joint inflammation also demonstrate patient could receive systemic therapy infliximab . These report examine effect single injection infliximab100 mg inject large inflame joint 2 IA injection 24 hour apart . We propose evaluate use IA infliximab patient intractable knee monoarthritis , explore optimal mode employment , assess degree infliximab systemic absorption IA injection . In pilot study 40 knee evaluate , 20 inject infliximab 20 injected corticosteroid comparator reflect current standard care .</brief_summary>
	<brief_title>Intraarticular Injection Infliximab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Have noninfectious monoarthritis knee inadequate response IA injection corticosteroid , least 3 month enrollment . Have oligo polyarthritis control disease modify agent ( DMARDs ) residual 12 inflamed joint , one knee inadequate response IA injection corticosteroid within 3 month Have negative PPD skin test . Have evidence TB chest xray . Be negative HBsAg HCV . No evidence infectious arthritis Known allergy infliximab . Known allergy lidocaine . Pregnant . Female patient childbearing potential practice effective method contraception . Suffer chronic infection . On systemic anti TNFα biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Intraarticular injection</keyword>
	<keyword>Infliximab</keyword>
</DOC>